# Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

> **NCT01769209** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 18 (actual)

## Conditions studied

- B-cell Adult Acute Lymphoblastic Leukemia (ALL)
- Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)
- Recurrent Adult Acute Lymphoblastic Leukemia (ALL)
- T-cell Adult Acute Lymphoblastic Leukemia (ALL)

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Doxorubicin hydrochloride (HCl)
- **DRUG:** PEG-Asparaginase
- **DRUG:** Vincristine sulfate
- **DRUG:** Dexamethasone
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01769209
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2016-11-25
- **Final completion:** 2017-07-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01769209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01769209, "Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01769209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*